{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=24", "query": { "intervention": "ipilimumab", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 640, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ipilimumab&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T11:13:59.821Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06866262", "title": "Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Clear Cell Renal Cell Carcinoma", "Locally Advanced Sarcomatoid Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Inulin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DIETARY_SUPPLEMENT", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2025-08-15", "completion_date": "2031-08-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06866262" }, { "nct_id": "NCT03149159", "title": "Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Steriotactic radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-04-01", "completion_date": "2018-04-01", "has_results": false, "last_update_posted_date": "2018-06-18", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03149159" }, { "nct_id": "NCT04132817", "title": "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-09-22", "completion_date": "2022-08-15", "has_results": false, "last_update_posted_date": "2022-12-02", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 8, "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04132817" }, { "nct_id": "NCT02869789", "title": "An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Nivolumab in combination with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1041, "start_date": "2016-10-05", "completion_date": "2022-05-13", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 61, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02869789" }, { "nct_id": "NCT01497808", "title": "RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-11-29", "completion_date": "2015-10-12", "has_results": true, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497808" }, { "nct_id": "NCT07075120", "title": "Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Ipilimumab and Nivolumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-04-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 2, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT07075120" }, { "nct_id": "NCT02174172", "title": "A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Interferon alfa-2b", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "PEG-interferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2014-08-18", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02174172" }, { "nct_id": "NCT07215962", "title": "Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Nivolumab + ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab + ipilimumab + platinum-based chemotherapy", "type": "BIOLOGICAL" }, { "name": "Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy", "type": "BIOLOGICAL" }, { "name": "Other dual-immuno-oncology therapy with chemotherapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2024-11-22", "completion_date": "2026-03-01", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 1, "location_summary": "Fleming Island, Florida", "locations": [ { "city": "Fleming Island", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215962" }, { "nct_id": "NCT00083278", "title": "Study of MDX-010 in Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "MDX-010", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 33, "start_date": "2003-05", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2012-04-27", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 14, "location_summary": "San Diego, California • Indianapolis, Indiana • Jeffersonville, Indiana + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Jeffersonville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083278" }, { "nct_id": "NCT05004025", "title": "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Uveal Melanoma" ], "interventions": [ { "name": "Novocure Optune", "type": "DEVICE" }, { "name": "Opdivo", "type": "DRUG" }, { "name": "Yervoy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2022-02-28", "completion_date": "2025-07-23", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-10-28T11:13:59.821Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Los Angeles, California", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05004025" } ] }